PAHC
Price
$31.98
Change
-$0.66 (-2.02%)
Updated
Aug 27, 11:37 AM (EDT)
Capitalization
1.32B
Earnings call today
VTRS
Price
$10.35
Change
-$0.06 (-0.58%)
Updated
Aug 27, 11:48 AM (EDT)
Capitalization
12.14B
75 days until earnings call
Interact to see
Advertisement

PAHC vs VTRS

Header iconPAHC vs VTRS Comparison
Open Charts PAHC vs VTRSBanner chart's image
Phibro Animal Health
Price$31.98
Change-$0.66 (-2.02%)
Volume$600
Capitalization1.32B
Viatris
Price$10.35
Change-$0.06 (-0.58%)
Volume$4.17K
Capitalization12.14B
PAHC vs VTRS Comparison Chart in %
Loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAHC vs. VTRS commentary
Aug 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Hold and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 27, 2025
Stock price -- (PAHC: $32.64 vs. VTRS: $10.41)
Brand notoriety: PAHC and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PAHC: 118% vs. VTRS: 105%
Market capitalization -- PAHC: $1.32B vs. VTRS: $12.14B
PAHC [@Pharmaceuticals: Generic] is valued at $1.32B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.14B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • PAHC’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than PAHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 5 bearish.
  • VTRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than PAHC.

Price Growth

PAHC (@Pharmaceuticals: Generic) experienced а +2.48% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -1.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.10%. For the same industry, the average monthly price growth was +10.13%, and the average quarterly price growth was +77.76%.

Reported Earning Dates

PAHC is expected to report earnings on Aug 27, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.1B) has a higher market cap than PAHC($1.32B). VTRS has higher P/E ratio than PAHC: VTRS (236.20) vs PAHC (40.95). PAHC YTD gains are higher at: 56.982 vs. VTRS (-13.145). PAHC has higher annual earnings (EBITDA): 123M vs. VTRS (-493.3M). VTRS has more cash in the bank: 406M vs. PAHC (70.4M). PAHC has less debt than VTRS: PAHC (770M) vs VTRS (14.5B). VTRS has higher revenues than PAHC: VTRS (14.1B) vs PAHC (1.19B).
PAHCVTRSPAHC / VTRS
Capitalization1.32B12.1B11%
EBITDA123M-493.3M-25%
Gain YTD56.982-13.145-433%
P/E Ratio40.95236.2017%
Revenue1.19B14.1B8%
Total Cash70.4M406M17%
Total Debt770M14.5B5%
FUNDAMENTALS RATINGS
PAHC vs VTRS: Fundamental Ratings
PAHC
VTRS
OUTLOOK RATING
1..100
2021
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
56100
SMR RATING
1..100
6395
PRICE GROWTH RATING
1..100
3946
P/E GROWTH RATING
1..100
891
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is in the same range as PAHC (27) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's Profit vs Risk Rating (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that PAHC’s stock grew somewhat faster than VTRS’s over the last 12 months.

PAHC's SMR Rating (63) in the Pharmaceuticals Major industry is in the same range as VTRS (95) in the null industry. This means that PAHC’s stock grew similarly to VTRS’s over the last 12 months.

PAHC's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as VTRS (46) in the null industry. This means that PAHC’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for PAHC (89) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCVTRS
RSI
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
57%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
66%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
62%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
62%
Advances
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend 6 days ago
67%
Declines
ODDS (%)
Bearish Trend 22 days ago
71%
Bearish Trend 1 day ago
65%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
60%
Aroon
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
51%
View a ticker or compare two or three
Interact to see
Advertisement
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HBTA26.880.23
+0.86%
Horizon Expedition Plus ETF
SVXY49.000.16
+0.33%
ProShares Short VIX Short-Term Futures
PAUG41.800.10
+0.24%
Innovator U.S. Equity Power BufferETFAug
SDD13.52-0.06
-0.42%
ProShares UltraShort SmallCap600
JDST7.30-0.29
-3.82%
Direxion Daily Jr Gld Mnrs Bear 2X ETF

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+2.19%
AMRX - PAHC
48%
Loosely correlated
+1.08%
PBH - PAHC
44%
Loosely correlated
+1.14%
ZTS - PAHC
43%
Loosely correlated
-0.26%
ELAN - PAHC
39%
Loosely correlated
+0.62%
VTRS - PAHC
38%
Loosely correlated
-1.33%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-1.33%
ELAN - VTRS
53%
Loosely correlated
+0.62%
ZTS - VTRS
46%
Loosely correlated
-0.26%
AMRX - VTRS
44%
Loosely correlated
+1.08%
EBS - VTRS
39%
Loosely correlated
-5.33%
PAHC - VTRS
38%
Loosely correlated
+2.19%
More